Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18

We sought to evaluate performance of a noninvasive prenatal test for fetal trisomy 21 (T21) and trisomy 18 (T18). A multicenter cohort study was performed whereby cell-free DNA from maternal plasma was analyzed. Chromosome-selective sequencing on chromosomes 21 and 18 was performed with reporting of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of obstetrics and gynecology Jg. 207; H. 2; S. 137.e1 - 137.e8
Hauptverfasser: Norton, Mary E., Brar, Herb, Weiss, Jonathan, Karimi, Ardeshir, Laurent, Louise C., Caughey, Aaron B., Rodriguez, M. Hellen, Williams, John, Mitchell, Michael E., Adair, Charles D., Lee, Hanmin, Jacobsson, Bo, Tomlinson, Mark W., Oepkes, Dick, Hollemon, Desiree, Sparks, Andrew B., Oliphant, Arnold, Song, Ken
Format: Journal Article
Sprache:Englisch
Veröffentlicht: New York, NY Mosby, Inc 01.08.2012
Elsevier
Schlagworte:
ISSN:0002-9378, 1097-6868, 1097-6868
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We sought to evaluate performance of a noninvasive prenatal test for fetal trisomy 21 (T21) and trisomy 18 (T18). A multicenter cohort study was performed whereby cell-free DNA from maternal plasma was analyzed. Chromosome-selective sequencing on chromosomes 21 and 18 was performed with reporting of an aneuploidy risk (High Risk or Low Risk) for each subject. Of the 81 T21 cases, all were classified as High Risk for T21 and there was 1 false-positive result among the 2888 normal cases, for a sensitivity of 100% (95% confidence interval [CI], 95.5–100%) and a false-positive rate of 0.03% (95% CI, 0.002–0.20%). Of the 38 T18 cases, 37 were classified as High Risk and there were 2 false-positive results among the 2888 normal cases, for a sensitivity of 97.4% (95% CI, 86.5–99.9%) and a false-positive rate of 0.07% (95% CI, 0.02–0.25%). Chromosome-selective sequencing of cell-free DNA and application of an individualized risk algorithm is effective in the detection of fetal T21 and T18.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0002-9378
1097-6868
1097-6868
DOI:10.1016/j.ajog.2012.05.021